Patents Assigned to St. Jude Children's Research Hospital
  • COORDINATED METABOLIC REPROGRAMMING IN RESPONSE TO PRODUCTIVE VIRAL INFECTIONS
    Publication number: 20170304293
    Abstract: The invention generally relates to methods of treating viral infections using known drugs and pharmaceutical compositions comprising same. More specifically, the disclosed methods are useful for the treatment of viral infections that are enveloped viruses. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention.
    Type: Application
    Filed: October 16, 2015
    Publication date: October 26, 2017
    Applicant: ST. JUDE CHILDREN'S RESEARCH HOSPITAL
    Inventors: Heather S. Smallwood, Marie Morfouace, Martine F. Roussel, Paul G. Thomas
  • System design and method for verifying 3D dosimetric imaging of charged particles in media
    Patent number: 9789339
    Abstract: A method of verifying therapeutic proton beam delivery accuracy by ultrasound tomographic imaging to map three dimensional (3D) proton dose through the detection of ionizing radiation induced thermo-acoustic signal from the proton beam.
    Type: Grant
    Filed: December 6, 2016
    Date of Patent: October 17, 2017
    Assignees: Purdue Research Foundation, St. Jude Children's Research Hospital, Inc.
    Inventors: Vadim Moskvin, Keith Michael Stantz
  • Methods and compositions for identifying minimal residual disease in acute lymphoblastic leukemia
    Patent number: 9777332
    Abstract: This invention provides methods and kits for diagnosing, ascertaining the clinical course of minimal residual disease associated with acute lymphoblastic leukemia (ALL). Specifically the invention provides methods and kits useful in the diagnosis and determination of clinical parameters associated with diseases associated with ALL based on patterns of surface marker expression unique to ALL.
    Type: Grant
    Filed: March 14, 2012
    Date of Patent: October 3, 2017
    Assignee: St. Jude Children's Research Hospital
    Inventors: Dario Campana, Elaine Coustan-Smith
  • Optimised coding sequence and promoter
    Patent number: 9764045
    Abstract: An optimized coding sequence of human blood clotting factor eight (VIII) and a promoter may be used in vectors, such as rAAV, for introduction of factor VIII, and/or other blood clotting factors and transgenes. Exemplary of these factors and transgenes are alpha-1-antitrypsin, as well as those involved in the coagulation cascade, hepatocye biology, lysosomal storage, urea cycle disorders, and lipid storage diseases. Cells, vectors, proteins, and glycoproteins produced by cells transformed by the vectors and sequence, may be used in treatment.
    Type: Grant
    Filed: April 7, 2015
    Date of Patent: September 19, 2017
    Assignees: UCL BUSINESS PLC, THROMBOSIS RESEARCH INSTITUTE, ST. JUDE CHILDREN'S RESEARCH HOSPITAL
    Inventors: Amit Nathwani, Natalie Ward, Adrian Thrasher, Edward Tuddenham, John Mcvey, John Gray, Andrew Davidoff
  • Anticancer compounds
    Patent number: 9682993
    Abstract: In one aspect, the invention relates to compounds having anticancer activity; synthetic methods for making the compounds; pharmaceutical compositions comprising the compounds; and methods of treating disorders associated with uncontrolled cellular proliferation using the compounds and compositions. This abstract is intended to be used as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention.
    Type: Grant
    Filed: December 9, 2013
    Date of Patent: June 20, 2017
    Assignee: St. Jude Children's Research Hospital
    Inventors: Thomas R Webb, Chandraiah Lagisetti
  • Genetically Engineered Swine Influenza Virus And Uses Thereof
    Publication number: 20170151324
    Abstract: The present invention relates, in general, to attenuated swine influenza viruses having an impaired ability to antagonize the cellular interferon (IFN) response, and the use of such attenuated viruses in vaccine and pharmaceutical formulations. In particular, the invention relates to attenuated swine influenza viruses having modifications to a swine NS1 gene that diminish or eliminate the ability of the NS1 gene product to antagonize the cellular IFN response. These viruses replicate in vivo, but demonstrate decreased replication, virulence and increased attenuation, and therefore are well suited for use in live virus vaccines, and pharmaceutical formulations.
    Type: Application
    Filed: December 12, 2016
    Publication date: June 1, 2017
    Applicants: Icahn School of Medicine at Mount Sinai, St. Jude Children's Research Hospital, The United States of America, As Represented by the Secretary of Agriculture
    Inventors: Peter Palese, Adolfo Garcia-Sastre, Richard J. Webby, Juergen A. Richt, Robert G. Webster, Kelly M. Lager
  • Modified Sendai virus vaccine and imaging vector
    Patent number: 9637758
    Abstract: The present invention relates to a Sendai virus or recombinant Sendai virus vector. In particular the present invention provides methods, vectors, formulations, compositions, and kits for a modified Enders strain Sendai viral vector. An immunogenic vector can be used in any in vitro or in vivo system. Moreover, some embodiments include vectors for imaging virus growth, location and transmission.
    Type: Grant
    Filed: April 13, 2012
    Date of Patent: May 2, 2017
    Assignee: St. Jude Children's Research Hospital
    Inventors: Julia Lea Hurwitz, Toru Takimoto, Charles John Russell, Allen Portner, Karen Slobod
  • CHIMERIC RECEPTOR WITH NKG2D SPECIFICITY FOR USE IN CELL THERAPY AGAINST CANCER AND INFECTIOUS DISEASE
    Publication number: 20170107491
    Abstract: The invention provides a chimeric receptor comprising NKG2D, DAP10 and CD3 zeta. Also disclosed is a composition comprising this chimeric receptor and methods for making and using it to enhance the cytotoxicity and antitumor capacity of NK cells. The invention also encompansses methods for use of NKG2D-DAP10-CD3 zeta polypeptides, vectors and cells in methods for treating cancer and other proliferative disorders, as well as infectious diseases.
    Type: Application
    Filed: October 28, 2016
    Publication date: April 20, 2017
    Applicants: ST. JUDE CHILDREN'S RESEARCH HOSPITAL, INC., NATIONAL UNIVERSITY OF SINGAPORE
    Inventors: Dario Campana, Yu-Hsiang Chang
  • Chimeric receptors with 4-1BB stimulatory signaling domain
    Patent number: 9605049
    Abstract: The present invention relates to a chimeric receptor capable of signaling both a primary and a co-stimulatory pathway, thus allowing activation of the co-stimulatory pathway without binding to the natural ligand. The cytoplasmic domain of the receptor contains a portion of the 4-1BB signaling domain. Embodiments of the invention relate to polynucleotides that encode the receptor, vectors and host cells encoding a chimeric receptor, particularly including T cells and natural killer (NK) cells and methods of use.
    Type: Grant
    Filed: June 10, 2014
    Date of Patent: March 28, 2017
    Assignee: St. Jude Children's Research Hospital, Inc.
    Inventors: Dario Campana, Chihaya Imai
  • Compounds for inhibiting 1-deoxy-D-xylulose-5-phosphate reductoisomerase
    Patent number: 9593136
    Abstract: In particular, the compound is effective to inhibit Dxr in Mycobacterium tuberculosis (Mtb). The present invention relates to compounds having general formula (I) or (II) where X is an acidic group, such as carboxylate, phosphonate, sulfate, and tetrazole; Ar is a substituted or unsubstituted aromatic or heteroaromatic group; and n is 0, 1, 2, 3, or 4, preferably 2, 3, or 4. The compounds inhibits 1-deoxy-D-xylulose-5-phosphate reductoisomerase (Dxr), particularly Dxr in Mycobacterium tuberculosis (Mtb).
    Type: Grant
    Filed: June 29, 2012
    Date of Patent: March 14, 2017
    Assignees: The George Washington University, George Mason University, St. Jude Children's Research Hospital, Inc., The United States of America, as Represented by the Secretary, Department of Health and Human Services
    Inventors: Helena I. Boshoff, Cynthia S. Dowd, Emily R. Jackson, Kylene Kehn-Hall, Richard E. Lee, Robin Lee, Geraldine San Jose
  • Methods and compositions of p27transcriptional modulators
    Patent number: 9572815
    Abstract: In one aspect, the invention relates to pharmaceutical compositions comprising agents that activate the expression of Atoh1, or pharmaceutically acceptable salts, solvates, or polymorphs thereof; and agents that inhibit the expression of p27Kip1, or pharmaceutically acceptable salts, solvates, or polymorphs thereof, which are useful for inducing the formation of cochlear hair cells; and methods of treating hearing impairments or disorders using the compositions. In one aspect, the invention relates to pharmaceutical compositions comprising ?-catenin; and agents that activate the expression of Atoh1, or pharmaceutically acceptable salts, solvates, or polymorphs thereof. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention.
    Type: Grant
    Filed: March 15, 2014
    Date of Patent: February 21, 2017
    Assignee: St. Jude Children's Research Hospital
    Inventors: Jian Zuo, Taosheng Chen, Brandon Walters, Bryan Kuo, Bradley Walters
  • METHODS OF EXPANDING EX VIVO NATURAL KILLER T (NKT) CELLS AND THERAPEUTIC USES THEREOF
    Publication number: 20170029777
    Abstract: The present invention is directed to novel methods of producing ex vivo natural killer T (NKT) cells, and therapeutic uses thereof for treatment of certain conditions including cancer, autoimmunity, inflammatory disorders, allergic disorders, tissue transplant-related disorders, and infections.
    Type: Application
    Filed: January 23, 2015
    Publication date: February 2, 2017
    Applicant: ST. JUDE CHILDREN'S RESEARCH HOSPITAL, INC.
    Inventor: Asha PILLAI
  • Genetically engineered swine influenza virus and uses thereof
    Patent number: 9549975
    Abstract: The present invention relates, in general, to attenuated swine influenza viruses having an impaired ability to antagonize the cellular interferon (IFN) response, and the use of such attenuated viruses in vaccine and pharmaceutical formulations. In particular, the invention relates to attenuated swine influenza viruses having modifications to a swine NS1 gene that diminish or eliminate the ability of the NS1 gene product to antagonize the cellular IFN response. These viruses replicate in vivo, but demonstrate decreased replication, virulence and increased attenuation, and therefore are well suited for use in live virus vaccines, and pharmaceutical formulations.
    Type: Grant
    Filed: March 3, 2015
    Date of Patent: January 24, 2017
    Assignees: Icahn School of Medicine at Mount Sinai, St. Jude Children's Research Hospital, The United States of America, as Represented by the Secretary of Agriculture
    Inventors: Peter Palese, Adolfo Garcia-Sastre, Richard J. Webby, Juergen A. Richt, Robert G. Webster, Kelly M. Lager
  • System design and method for verifying 3D dosimetric imaging of charged particles in media
    Patent number: 9545527
    Abstract: A method of verifying therapeutic beam delivery accuracy by ultrasound tomographic imaging to map three dimensional (3D) dose through the detection of ionizing radiation induced thermo-acoustic signal from the proton beam.
    Type: Grant
    Filed: April 30, 2014
    Date of Patent: January 17, 2017
    Assignees: Purdue Research Foundation, St. Jude Children's Research Hospital, Inc.
    Inventors: Vadim Moskvin, Keith Michael Stantz
  • Therapies based on control of regulatory T cell stability and function via a neuropilin-1:semaphorin axis
    Patent number: 9540439
    Abstract: The invention is directed to treatment of cancer, infections and various inflammatory and autoimmune conditions by affecting regulatory T cell stability and function via a Neuropilin-1:Semaphorin axis. The present invention satisfies this and other needs by demonstrating that the regulatory T cell (Treg)-restricted neuropilin-1 (Nrp 1) interacts with the cell surface ligand semaphorin-4a (Sema4a) (e.g., on conventional T cells (Tconv), conventional dendritic cells (cDCs), and/or plasmacytoid dendritic cells (pDCs)) to potentiate reg function and enhance their survival at inflammatory sites.
    Type: Grant
    Filed: October 8, 2013
    Date of Patent: January 10, 2017
    Assignee: St. Jude Children's Research Hospital
    Inventors: Dario A. A. Vignali, Seng-ryong Woo, Greg M. Delgoffe
  • Method for detection of adenosine and metabolites thereof
    Patent number: 9528976
    Abstract: This invention relates is a label-free, enzyme-free, aptamer-free method for simultaneously measuring adenosine, and its intracellular metabolites, e.g., AMP, ADP and ATP, using high pressure liquid chromatography coupled to electrochemical detector (HPLC-ECD).
    Type: Grant
    Filed: February 28, 2014
    Date of Patent: December 27, 2016
    Assignee: St. Jude Children's Research Hospital
    Inventors: Amar K. Pani, Richard Jay Smeyne
  • Monoclonal antibodies to interleukin 35 and methods of use thereof to inhibit regulatory T cell function
    Patent number: 9518113
    Abstract: Methods for regulating T cell function in a subject, particularly regulatory T cell activity are provided. Methods of the invention include administering to a subject a therapeutically effective amount of an Interleukin 35-specific binding agent, such as an antibody or small molecule inhibitor. The invention further provides methods for enhancing the immunogenicity of a vaccine or overcoming a suppressed immune response to a vaccine in a subject, including administering to the subject a therapeutically effective amount of an IL35-specific binding agent and administering to the subject a vaccine. In one embodiment the vaccine is a cancer vaccine.
    Type: Grant
    Filed: July 10, 2015
    Date of Patent: December 13, 2016
    Assignee: St. Jude Children's Research Hospital
    Inventors: Dario Vignali, Creg Workman, Lauren Collison, Kate Vignali
  • Chimeric receptor with NKG2D specificity for use in cell therapy against cancer and infectious disease
    Patent number: 9511092
    Abstract: The invention provides a chimeric receptor comprising NKG2D, DAP10 and CD3 zeta. Also disclosed is a composition comprising this chimeric receptor and methods for making and using it to enhance the cytotoxicity and antitumor capacity of NK cells. The invention also encompasses methods for the use of NKG2D-DAP10-CD3 zeta polypeptides, vectors and cells in methods for treating cancer and other proliferative disorders, as well as infectious diseases.
    Type: Grant
    Filed: January 28, 2014
    Date of Patent: December 6, 2016
    Assignees: St. Jude Children's Research Hospital, Inc., National University of Singapore
    Inventors: Dario Campana, Yu-Hsiang Chang
  • ARYL SUBSTITUTED AMINOMETHYL SPECTINOMYCIN ANALOGS AS ANTIBACTERIAL AGENTS
    Publication number: 20160347762
    Abstract: The invention relates to aryl substituted aminomethyl spectinomycin analogs, derivatives thereof, and related compounds, which are useful as anti-bacterial agents; methods for making the compounds; pharmaceutical compositions comprising the compounds; and methods of treating anti-bacterial infections using the compounds and compositions.
    Type: Application
    Filed: September 29, 2014
    Publication date: December 1, 2016
    Applicant: ST. JUDE CHILDREN'S RESEARCH HOSPITAL, INC.
    Inventors: Richard E. Lee, Samanthi L. Waidyarachchi, David F. Bruhn, Jiuyu Liu, Zhong Zheng, Jason W. Rosch
  • Modified influenza virus for monitoring and improving vaccine efficiency
    Patent number: 9499850
    Abstract: The immunogenicity of the influenza virus hemagglutinin (HA) molecule may be increased by substitutions of amino acids in the HA sequence. The substitution of specific HA residues, such as asparagine at position 223 of H5 HA, increase the sensitivity of the hemagglutinin inhibition (HI) assay by altering receptor specificity and/or antibody-antigen binding. HA molecules containing such substitutions will be useful in the development of diagnostic reference viruses and improved influenza vaccines.
    Type: Grant
    Filed: October 3, 2013
    Date of Patent: November 22, 2016
    Assignee: St. Jude Children's Research Hospital
    Inventors: Erich Hoffmann, Aleksandr S. Lipatov, Richard J. Webby, Elena A. Govorkova, Robert G. Webster